Investment Analysts’ Weekly Ratings Updates for NervGen Pharma (NGEN)

A number of firms have modified their ratings and price targets on shares of NervGen Pharma (NASDAQ: NGEN) recently:

• 5/5/2026 – NervGen Pharma was upgraded by Wall Street Zen from “strong sell” to “sell”.
• 4/29/2026 – NervGen Pharma was upgraded by Zacks Research to “hold”.
• 4/28/2026 – NervGen Pharma was upgraded by HC Wainwright to “strong-buy”.
• 4/27/2026 – NervGen Pharma was downgraded by Wall Street Zen from “sell” to “strong sell”.
• 4/27/2026 – NervGen Pharma is now covered by HC Wainwright. They set a “buy” rating and a $18.00 price target on the stock.
• 4/24/2026 – NervGen Pharma is now covered by Weiss Ratings. They set a “sell (d-)” rating on the stock.
• 4/23/2026 – NervGen Pharma was upgraded by Stifel Nicolaus to “strong-buy”.

NervGen Pharma Corp. is a clinical-stage biotechnology company focused on developing therapies to promote nerve repair and restore neurological function following injury or disease. The company advances regenerative approaches intended to address damage in the central and peripheral nervous systems, pursuing programs that aim to translate preclinical repair concepts into human treatments.

The company’s lead investigational candidate is NVG-291, which is being evaluated in clinical studies for indications that include spinal cord injury, neuropathic conditions and neurodegenerative disease settings.